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Editorial on the Research Topic
Human and animal models for translational research on neurodegeneration: challenges and
opportunities from South America
NEURODEGENERATION: A VOICE FROM THE SOUTH
Facing the alarming growth of dementia and neurodegenerative conditions has become a critical
priority across the globe (Alzheimer’s Disease International, 2009; Lancet, 2015; Shah et al.,
2016; Parra et al., 2018). Neurodegenerative diseases are the most frequent cause of dementia,
representing a burden for public health systems (especially in middle and middle-high income
countries). Although most research on this subject is concentrated in first-world centers, growing
efforts in South American countries (SACs) are affording important breakthroughs. This emerging
agenda poses not only new challenges for the region, but also new opportunities for the field at
large. SACs have witnessed a promising development of relevant research in humans and animals,
giving rise to new regional challenges. As highlighted in a recent experts’ consensus paper Latin-
American countries (LAC), and SACs in particular (Parra et al., 2018), face a critical situation.
Higher demographic rates and the predicted prevalence of dementia have reached and even
exceeded those of developing countries. In SACs, low- and middle-income countries (e.g., Bolivia,
Paraguay), the prevalence of dementia will double that of high-income countries, while upper-
middle-income countries in the region (e.g., Argentina, Brazil, Chile, Colombia, Peru, Uruguay,
and Venezuela) will experience the greatest impact of dementia. The WHO estimated that the
standardized prevalence of dementia in Latin America was 8.5%, but multiple SACs have been
underrepresented or underestimated in such a calculation (Parra et al., 2018). Moreover, raw
prevalence rates across studies are characterized by high variability within and between countries
(e.g., Argentina: 8.3; Brazil: 7.1-2.0; Chile: 4.4-7.0; Colombia: 6.0; Peru: 6.72-9.3; Uruguay: 3.1;
Venezuela: 5.7-13,7) (Parra et al., 2018). In addition, most of these studies are undermined by
various limitations and methodological problems. Even considering these data, SACs possess the
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highest global prevalence of dementia after North Africa/Middle
East in people above the age of 60 (Parra et al., 2018). Moreover,
the harmonization of global strategies against dementia in these
contexts is hindered not only by reduced epidemiological data,
but also by the lack of standardized clinical practice, insufficient
training of physicians, limited resources, and poor governmental
support, let alone poverty and more general cultural barriers
and stigmas. All of these factors have impacted the type and
amount of research conducted in SACs. A regional network,
based on multi-institutional actors from research, governmental,
and private sectors is fundamental to overcome these challenges
(Parra et al., 2018).
Nevertheless, until now most research groups still work
in isolation or in sporadic collaboration, without developing
large-scale multicenter studies or active cooperation networks.
The field could grow exponentially by combining the strengths
of regional research with higher visibility, a translational
philosophy, and enhanced global networking. Importantly,
collaborative developments may promote the establishment of
translational centers studying neurodegeneration. This Research
Topic engages researchers from the world over, helping to
integrate the international community of experts and to establish
new challenges and developments for future investigation. We
present original research in SACs, including studies assessing
the interplay among genetic, neural, and behavioral dimensions
of these diseases, as well as articles on vulnerability factors,
comparisons of findings from various countries, and works
promoting multicenter and collaborative networking. More
generally, our Research Topic covers a broad scope of human
research approaches (behavioral assessment, neuroimaging,
electromagnetic techniques, brain connectivity, peripheral
measures), animal methodologies (genetics, epigenetics,
proteomics, metabolomics, other molecular biology tools), target
species (human and non-human animals, sporadic, and genetic
versions), and article types (mainly original research articles,
but also case reports, data reports, commentaries, opinions,
and reviews), all based on work conducted in SACs. Thus, in
capturing the breakthroughs, possibilities, and limitations of such
a promising niche, the present Research Topic (titledHuman and
animal models for translational research on neurodegeneration:
challenges and opportunities from South America) represents a
valuable forum to initialize a constructive dialogue and reflect
on the present and future of neurodegenerative research in the
region. Here, we summarize the main contributions included
in the volume. Through this wide-ranging proposal, we hope to
introduce a fresh approach to the challenges and opportunities of
research on neurodegeneration across these countries, focusing
on two overarching levels of evidence (human and animal
research), as summarized below.
STUDIES ON HUMANS
Concerning human research, SACs offer invaluable possibilities
to pursue neurogenetic studies and clinical trials. This region
possesses the world’s largest population of familial Alzheimer’s
and Huntington’s disease (AD and HD, respectively), among
others, alongside multiple novel and rare functional genomic
variants of other disorders. Moreover, poor socioeconomic
conditions in several communities provide a natural scenario to
study the role of vulnerability, resilience, and genetic-cultural
interaction on disease progression. These opportunities are
already being exploited by consolidated research groups in
Argentina, Chile, Colombia, Peru, and Brazil, among others, via
cutting-edge approaches which include connectomics, omics-
biomarkers, and neuropsychological assessment. Moreover, the
emerging cognitive neuroscience of neurodegeneration in the
region (Parra et al., 2010, 2015; Ibanez and Manes, 2012;
Baez et al., 2013, 2014a,b, 2015, 2016a,b, 2017; García-Cordero
et al., 2015, 2016; Melloni et al., 2015, 2016; Pietto et al.,
2016; Santamaría-García et al., 2016, 2017; Sedeño et al.,
2016, 2017; Abrevaya et al., 2017; Birba et al., 2017; Calvo
et al., 2017; Dottori et al., 2017; Garcia et al., 2017a; García
et al., 2017b,c; Ibáñez et al., 2017; García and Ibáñez, 2018;
Kumfor et al., 2018) has provided manifold pathways of
synergy with multimethodological approaches to genetic, clinic,
neuropsychological, and neuroscientific data.
The research on human neurodegeneration presented in this
collection includes works on: (a) global challenges to dementia,
from diagnosis to public health; (b) different dimensions
of assessment (low socio-educational levels, cultural and
competence-related variability, and robust evaluations to face
heterogeneous contexts); (c) neurodegeneration discrimination
and disease progression (through combinations of behavioral
measures, neuroscientific approaches, and biomarkers for
improving differential diagnosis between dementia subtypes), the
characterization of specific initial alterations in each disease, and
the identification of factors that manifest in early aging; and (d)
the impact of non-pharmacological interventions for dementia
using non-invasive brain stimulation.
Global Challenges and Public Health
A first group of studies assesses diverse aspects of the global
challenges related to dementia, from diagnosis to public health
at a regional level. After reviewing critical sociodemographic and
epidemiological data form LACs, Baez and Ibanez propose to
evaluate the plausibility of international expert recommendations
regarding dementias in these countries. Key issues of this
evaluation include diagnosis, demographic specificities of LACs,
lack of social awareness of these diseases, deficiencies in the
health system, the need for standardizing diagnostic practices,
and the existing barriers in terms of resources and cultural
factors. Similarly, Custodio et al. outline a challenging picture
of epidemiological data in LACs, evidencing the major impact
of unprecedented demographic changes and projections of
dementia for people between 65 and 69 years old. The situation
is worst for low-income people whose families cover the majority
of the cost related to the disease. This is even worse for illiterate
people, where the majority of the costs are covered by families.
Accordingly, the authors propose a critical assessment of regional
differences and similarities for the implementation of long-term
care policies and plans. For their own part, Cardona-Gómez
and Lopera assess the intertwine of novel animal and human
translational research on molecular targets and pre/clinical
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studies. Then they discuss on cases of pure and mixed dementias
in the region, and, finally, they recommend the implementation
of a protocol clarification policy for developing clinical trials and
local intervention strategies.
Multiple and Multimodal Assessment
Another set of articles focuses on various dimensions of
assessment, including the effects of low socioeconomic status
and educational level, the role of clinical competence, and
the relevance of trans-culturally valid tasks. The low detection
of dementia is a major problem in SACs, accentuated by
the lack of validated and standardized tools. In a cross-
sectional study, Custodio et al. evaluate the robustness of
the memory alteration test (MAT) in low-educated patients
with mild cognitive impairment (MCI) and AD by using
validity measures (sensitivity, specificity, and correctly classified
percentage), internal consistency (Cronbach’s alpha coefficient),
and concurrent validity (Pearson’s ratio coefficient between the
MAT and Clinical Dementia Rating scores). All measures, they
conclude, provide robust and adequate classification scores.
Some instruments, like the working memory binding (WMB)
task (Parra et al., 2009, 2010), seem to have high sensitivity and
specificity to detect AD in early stages. It has been suggested that
cultural aspects such as education, age, and memory abilities may
impact in relatively culture-free tasks (Parra et al., 2018). Building
on this line of research, Hoefeijzers et al. provide evidence
of a new WMB task composed by everyday items that is not
affected by education. This result suggests that the WMB test
may be culturally and educationally unbiased for the screening
of abnormal aging trajectories.
Neurodegenerative Diseases: Progression
and Differentiation
A third set of works integrates behavioral and neuroscientific
insights (including biomarker research) to examine differential
diagnosis across dementia subtypes, the characterization of
specific initial alterations for each disease, and the identification
of factors that impact early aging.
Russo et al. investigate whether memory recognition and
deferred recall measures of episodic memory, in combination
with cerebrospinal fluid (CSF) biomarkers, can predict the
conversion from MCI (397 amnestic-MCI patients of the
Alzheimer’s disease Neuroimaging Initiative, ADNI) to AD (at
24 months of follow-up). Predictive models of memory, together
with risk factors (age, sex, education, APOE genotype and
CSF biomarkers), evidence that memory measures alongside
amyloid biomarkers can predict the conversion of MCI to AD
in the ADNI cohort, especially when combined with amyloid
biomarkers. This highlights the relevance of a multimodal
approach to anticipate the MCI progression to dementia.
Guevara et al. introduce an ante-mortem method to
differentiate progressive supranuclear palsy (PSP) from
idiopathic Parkinson’s disease (IPD) at early stages. To this end,
the authors combine normalized measures of brain atrophy with
clinical metrics (Unified Parkinson’s Disease Rating Scale Part
III, Hoehn and Yahr, Clinical Global Impression for Disease
Severity Scale, and the Frontal Assessment Battery). Their results
show that whole-brain and gray matter volumes distinguished
PSP from IPD, and that clinical-imaging correlations were
indicative of clinical presentation and differentiation.
Campêlo et al. investigate the relationship among single
nucleotide polymorphisms of alpha-synuclein gene (SNCA)
and risk for PD in a Brazilian sample, considering potential
interactions with environmental factors and specific clinical
outcomes (cognitive, motor, and mood impairments). Their
findings confirm the association between SNCA and PD risk
(and early onset PD). Specific SNCA alleles were significantly
more frequent in PD patients with cognitive impairment, and
negative association with protective factors (cognitive activity
and smoking habits). This study constitutes the first description
of SNCA polymorphism and PD in a South-American sample.
The relation among familial antecedents of late-onset
AD (LOAD), cognitive impairment, and sleep patterns in
asymptomatic subjects was investigated by Abulafia et al. Middle-
aged children of patients with LOAD (O-LOAD), in comparison
with controls, displayed deficits in episodic memory and
language. Moreover, the former group showed a phase-delayed
rhythm of body temperature. Also, cognitive performance in
these subjects was associated with cardiac autonomic sleep-wake
variables (greater sympathetic activity at night was related to
worse cognitive performance).
Long-lasting neurofunctional influences during childhood
can impact pathological aging. Iron deficiency anemia (IDA)
is a marker of iron micronutrient deficit affecting myelination,
dopamine neurotransmission, and neuronal metabolism. Algarin
et al. explore the connection between IDA in infancy and altered
connectivity patterns of the default-mode network (DMN, an
aging-sensitive resting-state network) in young adults. Compared
to controls, participants with IDA evidenced atypical DMN
connectivity. These preliminary findings suggest that a common
nutritional problem among human infants may be important for
understanding aberrant aging mechanisms.
Senescence has been associated with metabolic changes
including mitochondrial fission and fusion events. Stab
et al. assess the cell senescence and structural remodeling of
mesenchymal stromal/stem cells (from human mitochondrial
tissue) isolated from adipose tissue in vitro. Cell morphology
aging was associated with an increase in β-galactosidase
activity. Old cells showed increased mitochondrial mass,
augmented superoxide production, and decreased mitochondrial
membrane potential. Morphological changes were related to
increases in mitochondrial fusion proteins, Mitofusion 1, and
Dynamin-related GTPase. Thus, aged, adipose tissue-derived
mitochondrial stem cells developed a senescent phenotype.
Non-invasive Brain Stimulation as
Non-pharmacological Interventions
A fourth set of studies evaluate the impact of non-
pharmacological interventions for dementia. Non-invasive
brain stimulation (NIBS) methods can induce plastic changes in
the brain and modulate cognitive functions in humans. Thus,
their potential use for early stages of dementia has become a
promissory strategy.
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Birba et al. conducted a systematic review of the effects of
NIBS on MCI and subjective cognitive impairment (SCI) in
preventing or delaying the development of AD. In particular,
they discuss the impact of NIBS on specific target functions,
including recognition of verbal and non-verbal stimuli, attention,
psychomotor speed, and everyday memory. Moreover, they
identify a number of methodological issues (differences among
tasks, designs, and samples size) that arguably underlie the mixed
results obtained so far. They also outline further methodological
approaches to boost the efficacy and specificity of NIBS in
MCI and SCI. These issues are critical for developing robust
treatments for both conditions.
Finally, another report by Birba et al. provides the first
evidence that direct electrical brain stimulation can enhance
performance in the working memory binding (WMB) task,
a sensitive tool for early AD. WMB deficits constitute a
robust clinical and preclinical marker of AD, associated with
early atrophy of posterior brain regions. Profiting from a
unique approach, the authors show that direct intracranial
electrical stimulation of the parietal cortex can induce a selective
improvement in WMB performance. These preliminary but
promising results promote new opportunities to improve binding
functions in preclinical AD through brain stimulation.
STUDIES ON ANIMALS
The region also constitutes a rich platform for developments via
animal research. Preclinical testing of new therapeutic concepts
has been difficult due to the lack of naturally occurring disease
models. Although availability of genetically engineered mouse
models has partly addressed this challenge, neurodegenerative
diseases rarely occur in non-human animals (Jucker, 2010); and
the causes of non-familial dementia are multifactorial and age-
related (Hurley et al., 2018). In consequence, non-genetic and
natural models of dementia are still required. Advances could be
made by studying species such as the Octodon degus, an endemic
rodent from Chile that spontaneously develops an analog of
dementia at behavioral and neurobiological levels (Ardiles et al.,
2012; Hurley et al., 2018). In addition, the O. degus can also
naturally develop several other conditions like diabetes mellitus
type 2, macular and retinal degeneration and atherosclerosis,
conditions that are often associated with aging and comorbid
disorders with dementia (Hurley et al., 2018). Consequently,
the O. degus is a suitable novel experimental model that can
be utilized for the development of disease-modifying treatments
for dementia. In addition, scientific efforts in the region have
been enhanced through newmodels from promising groups (e.g.,
single and double immunohistochemistry, inmunoblot, RT-PCR,
behavioral phenotyping, CNS lesioning techniques, neuronal
tracers for connectivity studies, small craniotomy for drug
delivery). These approaches are now fueled by the engagement
of international centers and the development of multicenter
alliances.
The section on animal research provides timely works
on regionally relevant topics. These include (a) natural
models of AD; (b) pathophysiological models of different
neurodegenerative conditions, such as frontotemporal dementia
(FTD), amyotrophic lateral sclerosis (ALS), and AD; (c) the role
of the proteostasis network in basic organisms; and (d) cognitive
interventions as early non-pharmacological therapeutics.
Natural Rodent Models of
Neurodegeneration
In a Data Report Article, Altimiras et al. offer the first
characterization of the O. degus’s brain transcriptome (in order
to support its use as a natural model of AD), together with a
comparison between the transcriptomes of AD-like and healthy
specimens. Of note, this work includes an unprecedented report
of whole transcriptome sequencing (RNA-seq) of the Octogon
degus brain. Results reveal differences in novel and previously
reported genes for AD and related disorders (CHRNA6, AMD1,
WISP1, COX8A, APOC-I, among others). In addition, the
comparison of human andO. degusAD-like brain transcriptomes
evidences multiple common genes in both species. These findings
highlight the relevance of this rodent species to foster progress in
AD research.
Braidy et al. use the O. degus model to evaluate the
biometal imaging and role of metal uptake transporters in AD
pathogenesis and aging. Their work hinges on the hypothesis
thatO. degusmay develop neuropathological abnormalities in the
distribution of redox active biometals, due to alterations in the
expression of lysosomal protein, major Fe/Cu transporters, and
selected Zn transporters (ZnTs and ZIPs). Using laser ablation
inductively coupled plasmamass spectrometry, they find elevated
quantitative images of biometals (Fe, Ca, Zn, Cu, and Al) in
the aged O. degus, which in turn showed an age-dependent
rise. Some of these metals were specifically enriched in the
cortex and hippocampus. Whole-brain extracts evidenced age-
related deregulation of metal trafficking pathways (impaired
lysosomal function, demonstrated by increased cathepsin D
protein expression). An age-related reduction in the expression
of subunit B2 of V-ATPase was also identified, alongside
significant increases in amyloid beta peptide 42 (Aβ42),
and metal transporter ATP13a2. Finally, enhanced expression
of transporter of divalent metal species, 5′-aminolevulinate
synthase 2 (ALAS2), and the proto-oncogene, FOSwas associated
with aging. Thus, these results suggest that transition metals in
the brainmay be enriched with age in theO. degus, and that metal
dyshomeostasis in specific brain regions may be related to age.
Pathophysiological Models of Different
Neurodegenerative Conditions
Two additional studies provide pathophysiological models of
FTD, ALS, and AD. FTD and ALS are both associated with TAR
DNA-binding protein 43 (TDP-43). To investigate the behavioral
phenotype associated with this proteinopathy, Alfieri et al.
implemented a transgenic (Tg) mouse model that conditionally
overexpresses human wild-type TDP 43 protein (hTDP-43-WT)
in forebrain neurons. They analyzed the motor, social, and
cognitive performance of this species. The young hTDP-43-WT
Tg mice presented a mild degree of spasticity. Analysis of social
and cognitive behavior showed a rapid installment of deficits in
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social interaction, working memory, and recognition memory.
After long-term (up to 12 months) transgene induction, a motor
phenotype (previously absent in younger mice) was identified.
Thus, this work points to the time-dependent emergence of a
motor phenotype, a clinical presentation of FTD with involving
motor deficits, and a complementary animal model for studying
TDP-43 proteinopathies.
The effect of chronic treatment with reserpine (an inhibitor
of vesicular monoamine transporter-2), which induces dyskinesia
in PD, has been proposed to be attenuated in spontaneously
hypertensive rats (SHRs). Leão et al. evaluated whether SHRs (in
comparison with Wistar rats) present differential susceptibility
to repeated reserpine-induced deficits in a progressive model
of PD. Only reserpine-treated Wistar rats presented increased
motor signs. After a withdrawal period, both strains recovered
from motor impairment, but SHRs were slower to reach control
levels. Immunohistochemistry for tyrosine hydroxylase (TH) and
α-synuclein (α-syn) after the last injection or 15 days after
withdrawal showed a reduction in TH and an increase in α-
syn immunoreactivity in the substantia nigra and dorsal striatum
(recovered after 15 days of withdrawal). The SHRs were resistant
to reserpine-induced TH decrement in the substantia nigra,
and presented reduced immunoreactivity to α-syn in the dorsal
striatum relative toWistar rats, irrespective of treatment. In brief,
SHRs may be resilient to motor and neurochemical impairments
induced by the repeated low-dose reserpine.
Accumulation of β in AD begins many years before clinical
onset. Yet, given that massive accumulation of Aβ appears in
30% of healthy aged individuals, compensatory mechanisms
and/or additional neurotoxic or protective factors need to be
discovered. Belfiori-Carrasco et al. provide a novel genetic
screen in the drosophila brain that identifies modifiers of age-
dependent amyloid β toxicity. One hundred and ninety-nine
deficiency lines accounting for ∼6,300 genes were analyzed.
Six lines significantly modified Aβ42 neurotoxicity, including
the CG11796 and CG17249 (orthologs to human HPD and
PRCC, respectively) as candidates. These modifiers of Aβ42
neurotoxicity in Drosophila open avenues for new validation
studies into their possible role in sporadic AD.
Proteostasis Network: From Animal to
Human Approaches
Abnormal protein aggregation is a transversal pathological
mechanism in neurodegeneration. Thus, the capacity of neurons
to handle alterations in the proteome seems to be specifically
altered in aging. Martínez et al. critically asses the proteostasis
network in basic organisms, highlighting the challenges for
moving toward human research in this domain. Although several
reports are pointing to this network as a relevant adjustor of
organismal aging in several species, its relevance to human aging
remains unknown. The authors discuss multiples challenges
(regarding buffering capacity, neural control of organismal
proteostasis, connections among stress and aging in protein
misfolding disorders, control the cell-nonautonomous UPR as a
therapeutic strategy) in the light of new drug-based avenues to
intervene in brain aging.
Cognitive Interventions as an Early
Non-pharmacological Strategy: From
Animal Research to Human Translation
To conclude, Gehres et al. set forth a challenging opinion
on cognitive interventions as an early non-pharmacological
strategy in AD, considering a translational perspective from
animal research to human behavior. The critical concepts of
cognitive reserve, cognitive interventions, and early-life exposure
to environmental enrichment (EE) are reviewed from the vantage
point of animal research, with new vistas for neurodegenerative
human conditions. After an informative revision, the authors
conclude that study designs that aim to unravel EE-specific
mechanisms are crucial and could guide the generation of non-
pharmacological strategies. Moreover, the combination of EE
with better models of sporadic AD, in conjunction with CSF/PET
biomarkers, could promote novel insights on novel therapeutic
targets for AD.
CONCLUSIONS
Amid a multiple collection of theories, experimental approaches,
and models, all these studies highlight both the rise of world-
class research in SACs, as well as the specificity of problems
and opportunities in the region. Moreover, they provide
relevant evidence for the harmonization of multilevel approaches
to neurodegenerative research. Overall, this integrated and
pluralistic approach to neurodegeneration in SACs can provide
the basic building blocks for a future translational network based
on (but not limited to) experimental research, focusing on policy
changes and the development of international collaborations
(Parra et al., 2018). In sum, this book demonstrates that SACs
are highly active in generating first-class translational and
multicenter research on neurodegeration, thus amplifying the
powerful voice of the South in this worldwide program.
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